The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
Manfred Johannsen(Charité - Universitätsmedizin Berlin), Filippo de Braud(University of Milan), Hartwig Kosmehl(Helios Klinikum Erfurt), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Eveline Trachsel(Swissmedic), Gabriele Pecher(Charité - Universitätsmedizin Berlin), Dario Neri(University of Siena), Jan Roigas(Klinikum im Friedrichshain), Leonardo Giovannoni(Philogen (Italy)), Gianluca Spitaleri(Institute of Oncology Research), Andreas Roemer(Charité - Universitätsmedizin Berlin), Patrik Rogalla(Charité - Universitätsmedizin Berlin), Christian Kloeters(Charité - Universitätsmedizin Berlin), Reinerio González‐Iglesias(Philogen (Italy)), Hans D. Menssen(Franklin University), Manuela Kaspar(Philochem (Switzerland)), Alexander Berndt(Jena University Hospital), Kurt Miller(Charité - Universitätsmedizin Berlin), Giuseppe Curigliano(European Institute of Oncology), Steffen Weikert(St. Hedwig-Krankenhaus), Valeria Lovato(Roche (Italy))
Cited by 187
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Interfering with pH regulation in tumours as a therapeutic strategy
|Nature Reviews Drug Discovery|2011|1.5k